Drug
Upacicalcet sodium hydrate clinical trials
Also written PLS240.
A product of Upacicalcet; its studies count on that page too.
- studies test it
- 3
- open now
- 1
- in phase 3
- 3
- first study started
- 2023
Keep track of what changes. Save the upacicalcet sodium hydrate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Pathalys Pharma (3)
Studies
Open first, then newest update. How each study uses upacicalcet sodium hydrate is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisNot yet recruitingPhase 3Pathalys PharmaNCT07890584Written as PLS240
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2CompletedPhase 3Pathalys PharmaNCT05836220Written as PLS240
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1CompletedPhase 3Pathalys PharmaNCT05832931Written as PLS240
Codes
What other systems call upacicalcet sodium hydrate · ClinicalTrials.gg INT016332
- UNII (FDA) DH9LW5L96PUPACICALCET SODIUM HYDRATEOne source FDA
- NCI Thesaurus C151955Upacicalcet Sodium HydrateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DH9LW5L96P | UPACICALCET SODIUM HYDRATE | One source FDA |
| NCI Thesaurus | C151955 | Upacicalcet Sodium Hydrate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.